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Sepsis is defined as life-threatening organ dysfunction
caused by a dysregulated host response to infection [1].
The syndrome is characterised by autonomic dysfunc-
tion and increased plasma levels of noradrenaline and
adrenaline [2]. These catecholamines originate mainly
from the activated sympathetic nervous system, but
also originate from the adrenal gland, gut, and immune
cells [3]. While necessary and life-saving in the early
fight or flight reaction to any insult, prolonged adrener-
gic stress is detrimental and contributes to organ dys-
function [4]. Strategies to reduce adrenergic stress have
been proposed (Table 1) under the umbrella term
decatecholaminisation.
Esmolol (Table 2) is a short-acting cardioselective
beta-1 adrenergic blocker which has been tested in sep-
tic animals and in preliminary studies in human sepsis
[5]. In the largest trial to date, Morelli et al. [6] enrolled
septic shock patients with tachycardia (>95 beats/min)
and an ongoing requirement for high-dose norepineph-
rine despite 24 h of active resuscitation. In this high-risk
population (28-day mortality of 80.5 % in the control
group), esmolol titrated to control heart rate was both
safe and efficacious, reducing mortality to 49.4 %. The
observed decrease in norepinephrine requirements could
be mediated by a blunted immune response, resulting in
an improved microcirculation [7], or enhanced adrener-
gic receptor sensitivity [8].
Dexmedetomidine is a highly selective alpha-2 adre-
noreceptor agonist that has sedative, anxiolytic, and
opioid-sparing effects (Table 2) [9, 10]. The use of
dexmedetomidine in critically ill patients increased
ventilator-free time [11] and decreased the incidence
of postoperative complications, delirium, and mortality
up to 1 year post-cardiac surgery [12]. In postoperative
patients, dexmedetomidine provided sympatholytic ac-
tivity [13]. It also offers anti-inflammatory and organ
protective effects in animal models [14]. The use of
dexmedetomidine as an anti-adrenergic strategy in
sepsis has been evaluated in a recently completed mul-
ticentre Japanese study (‘DESIRE’, https://clinicaltrials.-
gov/ct2/show/NCT01760967; last accessed 28 August
2016) for which results are still eagerly awaited.
In this issue of Critical Care, Hernandez et al. [15]
tested both esmolol and dexmedetomidine in a sheep
model of endotoxic shock with systemic hypotension,
pulmonary hypertension, and hyperlactataemia. After
a brief phase of fluid resuscitation and haemodynamic
stabilisation with norepinephrine, animals were rando-
mised to receive dexmedetomidine, esmolol, or pla-
cebo. Despite the early use of sympatholytic drugs,
systemic and regional haemodynamics were main-
tained in the interventional groups compared to the
control group over the 2-h study period. Although
heart rate was significantly reduced by esmolol, car-
diac output, mean arterial pressure, noradrenaline
requirements, and SvO2 did not differ from placebo-
treated animals. Dexmedetomidine reduced serum
adrenaline levels by almost 40 %. Both esmolol and
dexmedetomidine reduced arterial and portal vein lactate
levels and improved lactate clearance. In summary, both
drugs were well tolerated from a haemodynamic point of
view and associated with likely beneficial effects on
metabolism.
These observations are particularly interesting as
dexmedetomidine and esmolol were started very early
after shock induction. However, the short duration of
the study precludes knowledge of longer term effects
and any impact on outcomes. Furthermore, it would
have been fascinating to have a fourth experimental
group exploring possible synergism between esmolol
and dexmedetomidine, as a rationale could be argued
for the use of both. Certainly it is premature to trans-
late these findings to clinical practice in septic pa-
tients, but this work should encourage further
research into the role of alpha-2 agonists in sepsis,
with or without beta-blockade.
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Table 1 Decatecholaminisation strategies for patients with septic shock
Strategy Recommendations
Blunt endogenous catecholamine release;
avoid compensatory adrenergic stimulation
Optimize cardiac preload and
vascular filling
Assess fluid status by leg-raise test
Perform repetitive fluid challenges to a target (e.g. stroke volume)
Use cardiac output monitoring and/or echocardiography
Treat hypoxia and severe
anaemia
Target oxygen saturation between 92–96 %
Transfuse red blood cells if haemoglobin falls below 70 g/l
Optimize sedation and
analgesia
Avoid over-sedation; use sedation targets
Interrupt sedation daily, especially if long-lasting sedatives
(e.g. midazolam) are used
Use dexmedetomidine (see text for details)
Reduce exogenous catecholamine administration Avoid excessive beta-mimetic
stimulation
Use cardiac output monitoring and/or echocardiography
Avoid supra-normal physiological targets
Only use inotropes if
contractility is impaired
Use cardiac output monitoring and/or echocardiography
Consider alternative drugs Consider alternative inotropes (e.g. levosimendan) and
vasopressors (e.g. vasopressin)
Accept abnormal physiological
values
Adjust therapeutic targets
Consider beta-blockers if
tachycardia persists
Prefer short-acting drugs (e.g esmolol, see text) that can be
stopped if adverse effects occur
Blunt inflammatory response (to reduce cardiac
depression and microvascular dysfunction)
Treat underlying infection Use intravenous antibiotics (after sampling for microbiology)
Push for urgent surgical/interventional source control
Reduce cytokine load Consider low-dose steroids
Consider extra-corporeal cytokine removal
Evidence and class of recommendations vary between the different interventions
Table 2 Pharmacological properties of the study drugs
Dexmedetomidine Esmolol
Characteristics Highly selective alpha-2 adrenoreceptor agonist Short-acting, selective beta-1 blocker
Mode of action Acts centrally, predominantly in the brain stem
(sedation) and in the spinal cord (analgesia)
Acts peripherally, predominantly in the heart
Effects Short- and long-term sedation in the intensive
care unit setting
Negative chronotropic, dromotropic, inotropic effects
Improves ventricular filling by prolonging diastole
Anxiolysis; opioid-sparing effect; anti-delirant effects Sympatholytic activity
Sympatholytic activity
Route of administration; dose Intravenous infusion: 0.2–1.4 μg/kg/h Loading
dose not recommended in clinical practice
Infusion: 25 mg/h, up-titration every 20 min in increments
of 50 mg/h, to reach the target heart rate of <95beats/min
Pharmacokinetics Half-life: 1.5 h Half-life: 9 min
Degradation by hepatic metabolism Degradation by unspecific esterases
No dose adjustments in renal dysfunction No dose adjustment in renal and/or hepatic dysfunction
Adverse haemodynamic effects Hypotension: 25 %, serious 1.7 % Symptomatic hypotension: 12 %
Hypertension: 15 % Haemodynamic deterioration in patients with compensatory
tachycardia
Bradycardia: 13 %, serious 0.9 %
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